Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

From the authors:

Y. Song, X. Li, X. Du
European Respiratory Journal 2010 35: 225-226; DOI: 10.1183/09031936.00147009
Y. Song
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
X. Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
X. Du
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

We would like to thank K. Inoue and H. Takano for their comments and questions regarding our paper entitled “Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma” 1.

We read with great interest the study mentioned by K. Inoue and H. Takano 2 with the knowledge that combined exposure to nanoparticles and endotoxin elicited devastating lung injury in comparison to nanoparticles or endotoxin alone. However, with regard to the patients in our study, no evidence was found to show that their symptoms might be related to endotoxin from their occupational exposure, our on-the-spot investigation, clinical observations and examinations, or long-term follow-up. If the patients had inhaled the endotoxin, some symptoms and signs of “endotoxin poisoning” would exist, such as fever, tiredness, headache or hypotension, but none of these were observed.

In general, two mechanisms are involved in the toxicity of nanoparticles. One mechanism is that nanoparticles themselves directly exert toxicities, which are related to the chemical component, size and shape of nanoparticles 3. When some nanomaterials gain entry into the body, either via inhalation, dermal or oral routes, and penetrate into cells, they can subsequently pose a series of cytotoxicities or promote DNA damage by several mechanisms 4. For example, nanoparticles can physically interact with the DNA molecule or proteins, which may lead to physical damage to the cell or genetic material. In addition, inflammation and oxidative stress (generation of reactive oxygen species) induced by nanoparticles have been identified as giving rise to effects on cell membranes, cytoplasm, nuclei and mitochondrial function 4, 5. Importantly, nanoparticles can damage cells through the regulation of redox-sensitive transcription factors, induction of apoptotic and necrotic cell death and decreased proliferation, and DNA damage responsive signalling 4–6. A recent study has shown that cationic starburst polyamidoamine dendrimer (PAMAM) nanoparticles trigger autophagic cell death by deregulating the Akt-TSC2-mTOR signalling pathway, and induce acute lung injury in vivo 7. The other mechanism of nanoparticle toxicity is that nanoparticles can be used as delivery carriers 8. In cancer and gene therapy, nanoparticles can deliver drugs at high concentrations to the sites of interest, e.g. cancer lesions. It is not difficult to understand that if the material the nanoparticles carry is not a drug but highly toxicant, it may cause potential damage to cells.

In our study, “nanoparticles were observed to lodge in the cytoplasm and caryoplasm of pulmonary epithelial and mesothelial cells” 1, direct interaction between nanoparticles and the DNA molecule or DNA-related proteins may lead to physical damage to the genetic material. In addition, nanoparticles may exert toxicities on cells by other mechanisms, such as inflammation, oxidative stress or cell responsive signalling. In order to question whether the lethal events resulted from the synergy of nanoparticls with other toxic substances, or to what extent the illnesses were due to particles and other toxic substances, further animal experiments need to be performed in order to draw a firm conclusion. However, in our opinion, as the workers were used the exposure of powder coatings, as well as other reasons discussed in the study 1, the major reason for illness may be due to the powder in the coating, which contains nanoparticles.

As for the rashes the patients experienced on their faces, these may show the physical damage caused by polyacrylate nanoparticles to skin. It is not appropriate to link them to pre-existing atopy or immunological impairment. The rashes on the face of patients, characterised by skin itching, pachylosis and breakage, varied greatly from the rashes experienced in patients with immune-related disorders, such as systemic lupus erythematosus, which were characterised by no inching but smooth and intact skin. Moreover, detailed clinical examinations and follow-up excluded the immune-related disorders or pre-existing atopy.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Song Y, Li X, Du X. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Respir J 2009;34:559–567.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Inoue K, Takano H, Yanagisawa R, et al. Effects of airway exposure to nanoparticles on lung inflammation induced by bacterial endotoxin in mice. Environ Health Perspect 2006;114:1325–1330.
      OpenUrlPubMedWeb of Science
    3. ↵
      Kirchner C, Liedl T, Kudera S, et al. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett 2005;5:331–338.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Singh N, Manshian B, Jenkins GJ, et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 2009;30:3891–3914.
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      Wang F, Gao F, Lan M, et al. Oxidative stress contributes to silica nanoparticle-induced cytotoxicity in human embryonic kidney cells. Toxicol In Vitro 2009;23:808–815.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Fröhlich E, Samberger C, Kueznik T, et al. Cytotoxicity of nanoparticles independent from oxidative stress. J Toxicol Sci 2009;34:363–375.
      OpenUrlCrossRefPubMedWeb of Science
    7. ↵
      Li C, Liu H, Sun Y, et al. PAMAM nanoparticles promote acute lung injury by inducing autophagic cell death through the Akt-TSC2-mtor signaling pathway. J Mol Cell Biol 2009;1:37–45.
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Vega-Villa KR, Takemoto JK, Yáñez JA, et al. Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev 2008;60:929–938.
      OpenUrlCrossRefPubMedWeb of Science
    PreviousNext
    Back to top
    View this article with LENS
    Vol 35 Issue 1 Table of Contents
    European Respiratory Journal: 35 (1)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    From the authors:
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    From the authors:
    Y. Song, X. Li, X. Du
    European Respiratory Journal Jan 2010, 35 (1) 225-226; DOI: 10.1183/09031936.00147009

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    From the authors:
    Y. Song, X. Li, X. Du
    European Respiratory Journal Jan 2010, 35 (1) 225-226; DOI: 10.1183/09031936.00147009
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Clinical outcomes of bronchiectasis in India
    • Reply: Clinical outcomes of bronchiectasis in India
    • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society